Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Rheumatol Rep. 2013 Jun;15(6):331. doi: 10.1007/s11926-013-0331-5.

Use of new oral anticoagulants in antiphospholipid syndrome.

Author information

1
Haemostasis Research Unit, Department of Haematology, University College London and University College London Hospitals NHS Foundation Trust, 51 Chenies Mews, London, WC1E 6HX, UK. d.arachchillage@ucl.ac.uk

Abstract

The current mainstay of treatment of thrombotic APS is long-term anticoagulation with oral vitamin K antagonists (VKA) such as warfarin. However, the use of warfarin is problematic, particularly in patients with antiphospholipid syndrome (APS). The new oral anticoagulants (NOAC) include dabigatran etexilate (Pradaxa®), a direct thrombin inhibitor, and rivaroxaban (Xarelto®), Apixaban (Eliquis) and Edoxaban (Lixiana®), which are direct anti-Xa inhibitors. Unlike warfarin, these agents do not interact with dietary constituents and alcohol, have few reported drug interactions, and monitoring of their anticoagulant intensity is not routinely required due to their predictable anticoagulant effects. In this chapter, we discuss clinical and laboratory aspects of NOAC. These agents have been approved for several therapeutic indications based on phase III prospective randomised controlled clinical trials using warfarin at a target INR of 2.5 (i.e. range 2.0-3.0) as the comparator. However these trials may not be directly applicable to patients with antiphospholipid syndrome (APS) where prospective clinical studies of NOAC are the way forward.

PMID:
23649961
DOI:
10.1007/s11926-013-0331-5
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center